Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Regulatory Science Infrastructure Gets $25 Million Push In Budget

Executive Summary

Gaining the expertise and infrastructure needed to assess products of the future - such as biosimilars and those based on stem cells and nanotechnology - is the goal of a $25 million scientific modernization effort proposed in the fiscal 2011 FDA budget

You may also be interested in...

FDA Budget To Rise By $418 Million In FY 11 As Congress Decides To Cut Spending Elsewhere

The agency budget reflects the federal government's responsibility for public health and safety, Senate Appropriations Committee explains.

Medical Product Safety Program Grows To $1.4 Billion In Proposed FDA FY '12 Budget

The agency also proposes to spend $49 million on its regulatory science initiative.

FDA Stem Cell Initiative Emphasizes Interaction With Industry, Outside Scientists

Exchange of information will facilitate product development in line with regulatory requirements, FDA says.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts